メディア掲載記事

An interview with ICON CFO Brendan Brennan on ICON’s $12B acquisition of PRA Health Sciences.

ICON has agreed to acquire PRA Health Sciences to broaden its abillity to provide decentralised and hybrid trial solutions.

ICON agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.

ICON will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for virtual clinical trials due to the pandemic.

In acquiring PRA, ICON would expand into digital and technology capabilities that are playing roles in clinical trials accelerated by the Covid-19 pandemic, such as virtual monitoring of study subjects as people stay at home and avoid public places.

ICON will acquire PRA Health Sciences for $12 billion in a move that will shake up the hightest rungs of a fragmented market.

The combined company will form the world’s largest contract research organisation, and is to be headquartered at ICON’s Leopardstown campus in Dublin.

ICON acquires PRA Health Sciences to form a world-leader CRO.

An article reporting on ICON's acquisition of contract research organisation PRA Health Sciences

ICON has announced one of the biggest takeover deals in Irish corporate history.